Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.

Micropapillary lung adenocarcinoma (MPA) has been reported as an aggressive variant of adenocarcinoma, frequently manifesting at high stage with a poor prognosis. We analyzed the clinical and molecular profile of 15 primary MPAs for K-ras, EGFR, and BRAF mutations and performed fluorescence in situ hybridization for EGFR amplification. In our study, 11 (73%) of 15 MPAs harbored mutually exclusive mutations: 5 (33%) K-ras, 3 (20%) EGFR, and 3 (20%) BRAF. Mutations in all 3 genes occurred in patients with a smoking history and tumors with mucinous differentiation and secondary lepidic, acinar, and solid growth, suggesting that in a Western population, cytomorphologic correlation with genetic mutations is more unpredictable than in Japanese cohorts. We conclude that K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[3]  Y. Ishikawa,et al.  High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs , 2005, Journal of Cancer Research and Clinical Oncology.

[4]  N. Moreno,et al.  Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. , 2008, Human pathology.

[5]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Askin,et al.  True papillary carcinoma of the lung: a distinct clinicopathologic entity. , 1997, The American journal of surgical pathology.

[7]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[8]  Y. Nishiwaki,et al.  Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. , 2000, Lung cancer.

[9]  M. Meyerson,et al.  Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[10]  William Pao,et al.  Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jungsil Ro,et al.  Micropapillary Component in Lung Adenocarcinoma: A Distinctive Histologic Feature With Possible Prognostic Significance , 2002, The American journal of surgical pathology.

[12]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[13]  S. Dacic,et al.  Gross Cystic Disease Fluid Protein—(GCDFP-15): Expression in Primary Lung Adenocarcinoma , 2008, The American journal of surgical pathology.

[14]  Y. Ishikawa,et al.  Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. , 2009, Lung cancer.

[15]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[16]  H. Iwasaki,et al.  Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours) , 2005, Histopathology.

[17]  N. Dhomen,et al.  New insight into BRAF mutations in cancer. , 2007, Current opinion in genetics & development.

[18]  S. Aida,et al.  Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types , 2004, Histopathology.

[19]  H. Iwasaki,et al.  Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors , 2007, Modern Pathology.

[20]  Setsuo Hirohashi,et al.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .

[21]  V. Trovisco,et al.  B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. , 2006, Human pathology.

[22]  M. Nikiforova,et al.  The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma , 2008, The American journal of surgical pathology.

[23]  三好 立,et al.  Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis , 2003 .

[24]  P. Bejarano.  Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma , 2010 .

[25]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Meyerson,et al.  Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.

[27]  W. Gerald,et al.  Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.

[28]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[29]  T. Chou,et al.  Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[30]  M. Roh,et al.  Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma , 2004, Histopathology.